BVT Aktienanleihe AMD 11.06.2024/ DE000VD06K02 /
2024-04-26 3:39:45 PM | Chg.+1.01 | Bid10:00:07 PM | Ask10:00:07 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
91.28EUR | +1.12% | - Bid Size: - |
- Ask Size: - |
ADVANCED MIC.DEV. D... | 165.33 - | 2024-06-11 | Call |
GlobeNewswire
04-25
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientif...
GlobeNewswire
04-18
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
GlobeNewswire
04-16
AMD Expands Commercial AI PC Portfolio to Deliver Leadership Performance Across Professional Mobile ...
GlobeNewswire
04-16
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...
GlobeNewswire
04-16
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
GlobeNewswire
04-15
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...
GlobeNewswire
04-09
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice Pre...
GlobeNewswire
04-09
AMD Extends Leadership Adaptive SoC Portfolio with New Versal Series Gen 2 Devices Delivering End-to...
GlobeNewswire
04-06
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...